Literature DB >> 21556026

Targeted therapies: denosumab--a new option for solid tumors metastatic to bone.

Philip J Saylor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21556026     DOI： 10.1038/nrclinonc.2011.70

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

Review 1.  Mechanisms of bone metastasis.

Authors:  G David Roodman
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

Review 2.  Osteoimmunology: interplay between the immune system and bone metabolism.

Authors:  Matthew C Walsh; Nacksung Kim; Yuho Kadono; Jaerang Rho; Soo Young Lee; Joseph Lorenzo; Yongwon Choi
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

3.  Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Authors:  David H Henry; Luis Costa; Francois Goldwasser; Vera Hirsh; Vania Hungria; Jana Prausova; Giorgio Vittorio Scagliotti; Harm Sleeboom; Andrew Spencer; Saroj Vadhan-Raj; Roger von Moos; Wolfgang Willenbacher; Penella J Woll; Jianming Wang; Qi Jiang; Susie Jun; Roger Dansey; Howard Yeh
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

4.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

5.  Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Authors:  Alison T Stopeck; Allan Lipton; Jean-Jacques Body; Guenther G Steger; Katia Tonkin; Richard H de Boer; Mikhail Lichinitser; Yasuhiro Fujiwara; Denise A Yardley; María Viniegra; Michelle Fan; Qi Jiang; Roger Dansey; Susie Jun; Ada Braun
Journal:  J Clin Oncol       Date:  2010-11-08       Impact factor: 44.544

6.  A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.

Authors:  Jean-Jacques Body; Thierry Facon; Robert E Coleman; Allan Lipton; Filip Geurs; Michelle Fan; Donna Holloway; Mark C Peterson; Pirow J Bekker
Journal:  Clin Cancer Res       Date:  2006-02-15       Impact factor: 12.531

7.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Ming Zheng
Journal:  J Natl Cancer Inst       Date:  2004-06-02       Impact factor: 13.506

Review 8.  RANK ligand as a therapeutic target for bone metastases and multiple myeloma.

Authors:  G David Roodman; William C Dougall
Journal:  Cancer Treat Rev       Date:  2007-10-26       Impact factor: 12.111

9.  Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates.

Authors:  Ana O Hoff; Béla B Toth; Kadri Altundag; Marcella M Johnson; Carla L Warneke; Mimi Hu; Ajay Nooka; Gilbert Sayegh; Valentina Guarneri; Kimberly Desrouleaux; Jeffrey Cui; Andrea Adamus; Robert F Gagel; Gabriel N Hortobagyi
Journal:  J Bone Miner Res       Date:  2008-06       Impact factor: 6.741
  9 in total
  2 in total

Review 1.  Denosumab--a powerful RANKL inhibitor to stop lytic metastases and other bone loss actions by osteoclasts.

Authors:  László Kopper
Journal:  Pathol Oncol Res       Date:  2012-05-16       Impact factor: 3.201

2.  Acrometastasis as the Initial Presentation of a KRAS-Positive Colon Cancer.

Authors:  Helen Gharwan; Lavanya Yarlagadda; Austin Duffy
Journal:  Case Rep Oncol       Date:  2012-07-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.